BioIntel is now The Catalyst Brief.
The Catalyst Brief
Coverage

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.

Page 42 of 43

Archive

US Overdose Deaths Show Decline Throughout Most of 2025, Offering Hope Amid EpidemicJan 14, 2026

US Overdose Deaths Show Decline Throughout Most of 2025, Offering Hope Amid Epidemic

The year 2025 marked a hopeful shift in the battle against drug overdose deaths in the United States, with federal data showing a decline across much of the year. This trend indicates that sustained public health and regulatory efforts may be yielding measurable benefits in a crisis that has impacted the nation for decades.

The Catalyst Brief
FDA Revises Safety Labeling for GLP-1 Weight Loss Drugs: Suicide Warnings RemovedJan 14, 2026

FDA Revises Safety Labeling for GLP-1 Weight Loss Drugs: Suicide Warnings Removed

In a significant regulatory update, the U.S. Food and Drug Administration (FDA) has asked Novo Nordisk and Eli Lilly, leading makers of GLP-1 receptor agonists used for weight management, to remove suicide warnings from their product labels. This decision follows exhaustive analysis of clinical data demonstrating no causal link between these drugs and suicidal thoughts or actions.

The Catalyst Brief
Veteran Regulator Richard Pazdur Warns of Political Chaos Harming FDA EffectivenessJan 13, 2026

Veteran Regulator Richard Pazdur Warns of Political Chaos Harming FDA Effectiveness

At a recent STAT event, Richard Pazdur, who departed the FDA after 26 years of service, delivered a stark warning regarding the current state of the FDA. He discussed how political influences and internal disarray are damaging the agency’s core functions and ability to safeguard public health. Pazdur's observations come at a critical time as regulatory policies and agency leadership face unprecedented scrutiny.

The Catalyst Brief
AbbVie, Amgen, and Lilly Call for FDA Updates to Post-Approval Change Rules to Support Pharma ReshoringJan 13, 2026

AbbVie, Amgen, and Lilly Call for FDA Updates to Post-Approval Change Rules to Support Pharma Reshoring

The push by major drugmakers to update FDA post-approval change rules highlights ongoing regulatory challenges that affect the pharmaceutical supply chain and manufacturing sovereignty. The companies' advocacy underscores the importance of regulatory adaptability to keep pace with industry needs and global supply dynamics, particularly as reshoring production gains prominence in policy discussions.

The Catalyst Brief
FDA Delays Expedited Submission Request for Stoke Therapeutics' Severe Epilepsy DrugJan 11, 2026

FDA Delays Expedited Submission Request for Stoke Therapeutics' Severe Epilepsy Drug

The dialogue between Stoke Therapeutics and the FDA surrounding the expedited review of a promising severe epilepsy drug underscores the complexities facing regulatory approvals in neurology. This development highlights ongoing tensions in balancing regulatory rigor with the urgent needs of patients with rare and debilitating conditions.

The Catalyst Brief
Opinion: The NIH Has Lost Its Scientific Integrity, Leading to Key Leadership ResignationsJan 11, 2026

Opinion: The NIH Has Lost Its Scientific Integrity, Leading to Key Leadership Resignations

The National Institutes of Health (NIH), a cornerstone of biomedical research and public health advancement, is currently facing a critical juncture as four leading officials have publicly resigned. Their departure raises important questions about scientific independence and institutional integrity amid alleged interference and censorship within the agency.

The Catalyst Brief
The NIH's Crisis of Integrity: Four Leaders Resign Over Scientific Interference and CensorshipJan 11, 2026

The NIH's Crisis of Integrity: Four Leaders Resign Over Scientific Interference and Censorship

The National Institutes of Health (NIH) has been a cornerstone of biomedical research innovation and public health advancement. However, recent resignations by four senior leaders spotlight serious concerns over editorial interference and censorship, raising questions about the organization's commitment to scientific rigor and transparency. This development underscores a growing apprehension within the biomedical community regarding governance and autonomy at one of the world's premier research institutions.

The Catalyst Brief
House Passes Extension of ACA Subsidies Amid Growing Bipartisan SupportJan 8, 2026

House Passes Extension of ACA Subsidies Amid Growing Bipartisan Support

With increasing backing from House Republicans, particularly those representing vulnerable districts, the subsidy extension aims to ease rising insurance premium costs. This development marks a pivotal moment in ongoing healthcare policy negotiations for 2026.

The Catalyst Brief

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.